NASDAQ:ESPR
Esperion Therapeutics Stock News
$2.36
-0.230 (-8.88%)
At Close: May 17, 2024
Northland Securities Thinks PolarityTE's Stock is Going to Recover
12:59pm, Wednesday, 08'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Buy rating on PolarityTE (PTE) today and set a price target of $8.00. The company's shares closed
Northland Securities Thinks PolarityTE’s Stock is Going to Recover
12:59pm, Wednesday, 08'th Apr 2020
Northland Securities analyst
Carl Byrnes
maintained a
Buy
rating on PolarityTE (
PTE
–
Research Report
) today and set a price target of
$8.00
. The company’s shares closed last Tuesday at $0.87,
Analysts Offer Insights on Healthcare Companies: Cutera (CUTR) and GW Pharma (GWPH)
11:33am, Wednesday, 08'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cutera (CUTR) and GW Pharma (GWPH). Cutera (CUTR) In a report released
Analysts Offer Insights on Healthcare Companies: Cutera (NASDAQ: CUTR) and GW Pharma (NASDAQ: GWPH)
11:33am, Wednesday, 08'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cutera (CUTR – Research Report)
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by Needham & Company LLC
09:36am, Wednesday, 08'th Apr 2020
Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Monday, AnalystRatings.com reports. They
Esperion's Cholesterol Drugs Receive Approval in Europe
02:43pm, Tuesday, 07'th Apr 2020
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Esperion's Cholesterol Drugs Receive Approval in Europe
02:43pm, Tuesday, 07'th Apr 2020
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Advisor Group Inc. Has $51,000 Stake in Esperion Therapeutics Inc (NASDAQ:ESPR)
08:50am, Tuesday, 07'th Apr 2020
Advisor Group Inc. decreased its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 33.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)
Needham Thinks Esperion's Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company's shares
Needham Thinks Esperion’s Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Esperion (
ESPR
–
Research Report
), with a price target of
$158.00
. The company’s shares closed last Monday at $32
Esperion announces European Commission approval of NUSTENDI tablet ESPR
11:38am, Monday, 06'th Apr 2020
Esperion announces European Commission approval of NUSTENDI tablet ESPR
Esperion announces European Commission approval of NILEMDO tablet ESPR
11:37am, Monday, 06'th Apr 2020
Esperion announces European Commission approval of NILEMDO tablet ESPR
